SYSTASY BIOSCIENCE GMBH

Their core work

Systasy Bioscience is a German biotech SME based near Munich that specializes in cell signaling research and psychiatric diagnostics. Their work spans from fundamental PDZ-mediated cell signaling mechanisms to applied molecular diagnostics for schizophrenia and pharmacogenetics in psychiatry. They contribute biomarker discovery and diagnostic tool development to EU research consortia, bridging the gap between basic neuroscience and clinical psychiatric applications.

What they specialise in

How they've shifted over time

Systasy began with fundamental research into PDZ-domain cell signaling (PDZnet, 2016) — a broad molecular biology topic with no direct clinical focus. By 2017, they pivoted toward psychiatric applications with schizophrenia biomarker research (SZ_TEST). Their most recent project (PSY-PGx, 2021) shows a clear shift toward clinical implementation, specifically pharmacogenetics-guided treatment in psychiatry. The trajectory is unmistakable: from basic cell biology toward applied psychiatric precision medicine.

Systasy is moving decisively from basic molecular research toward clinical psychiatric applications, particularly pharmacogenetics — expect future work in personalized mental health treatments.

How they like to work

Systasy operates exclusively as a participant, never as coordinator, which is typical for a specialist SME contributing specific technical capabilities to larger research efforts. With 34 unique consortium partners across 16 countries from just 3 projects, they work in large, diverse consortia — likely the Marie Curie training networks and research alliances their funding schemes indicate. This suggests they are a valued specialist that larger academic groups invite into their networks.

Despite only 3 projects, Systasy has built a remarkably wide network of 34 partners across 16 countries, reflecting the large multi-partner structure of MSCA training networks. Their reach is pan-European with no single geographic concentration.

What sets them apart

Systasy occupies a rare niche as a private SME working at the intersection of cell signaling science and psychiatric diagnostics — most companies in this space are either pure research or pure diagnostics, not both. Their progression from fundamental PDZ signaling to schizophrenia biomarkers to pharmacogenetics shows they can translate basic science into clinical tools. For consortium builders in mental health or precision psychiatry, they offer an industry partner with genuine bench-to-bedside capability.

Highlights from their portfolio

• PDZnet
  Largest single EC contribution (EUR 456K) and a Marie Curie training network, indicating Systasy's role in training the next generation of cell signaling researchers.
• PSY-PGx
  Most recent and forward-looking project, targeting the practical implementation of pharmacogenetics in psychiatry — a growing field with direct patient impact.
• SZ_TEST
  Bridges their earlier cell biology work with psychiatric diagnostics, focusing on early molecular detection of schizophrenia.